594 related articles for article (PubMed ID: 23962569)
21. Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Zhang Q; Wang HY; Liu X; Nunez-Cruz S; Jillab M; Melnikov O; Nath K; Glickson J; Wasik MA
J Immunol; 2019 Oct; 203(8):2043-2048. PubMed ID: 31534006
[TBL] [Abstract][Full Text] [Related]
22. Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Myklebust JH; Brody J; Kohrt HE; Kolstad A; Czerwinski DK; Wälchli S; Green MR; Trøen G; Liestøl K; Beiske K; Houot R; Delabie J; Alizadeh AA; Irish JM; Levy R
Blood; 2017 Feb; 129(6):759-770. PubMed ID: 28011673
[TBL] [Abstract][Full Text] [Related]
23. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
24. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
[TBL] [Abstract][Full Text] [Related]
25. Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL.
Ran F; Liu Y; Liu M; Zhang D; Wang P; Dong J; Tang W; Zhao G
Bioorg Chem; 2019 Aug; 89():102943. PubMed ID: 31031018
[TBL] [Abstract][Full Text] [Related]
26. Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Ran F; Liu Y; Chen X; Zhuo H; Xu C; Li Y; Duan X; Zhao G
Bioorg Chem; 2021 Jul; 112():104968. PubMed ID: 34000704
[TBL] [Abstract][Full Text] [Related]
27. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
[TBL] [Abstract][Full Text] [Related]
28. New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Rule S; Chen RW
Expert Rev Hematol; 2018 Sep; 11(9):749-756. PubMed ID: 30052472
[TBL] [Abstract][Full Text] [Related]
29. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.
Hershkovitz-Rokah O; Pulver D; Lenz G; Shpilberg O
Br J Haematol; 2018 May; 181(3):306-319. PubMed ID: 29359797
[TBL] [Abstract][Full Text] [Related]
31. A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
Romanchikova N; Strods A; Strazdina J; Strumfs B; Trapencieris P
Anticancer Res; 2016 Nov; 36(11):6133-6140. PubMed ID: 27793942
[TBL] [Abstract][Full Text] [Related]
32. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
34. Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
Nagel D; Bognar M; Eitelhuber AC; Kutzner K; Vincendeau M; Krappmann D
Oncotarget; 2015 Dec; 6(39):42232-42. PubMed ID: 26540570
[TBL] [Abstract][Full Text] [Related]
35. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.
Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L
Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438
[TBL] [Abstract][Full Text] [Related]
36. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
Moyo TK; Wilson CS; Moore DJ; Eischen CM
Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma.
Ran F; Liu Y; Yu S; Guo K; Tang W; Chen X; Zhao G
Bioorg Chem; 2020 Jan; 94():103367. PubMed ID: 31685258
[TBL] [Abstract][Full Text] [Related]
38. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
39. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
40. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Owen C; Berinstein NL; Christofides A; Sehn LH
Curr Oncol; 2019 Apr; 26(2):e233-e240. PubMed ID: 31043832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]